Forghieri et al., found a significantly higher magnitude of IFNγ-producing NPM1-mutated-specific T-cells in PB samples obtained in the allogeneic HSCT setting, compared to those observed in NPM1-mutated AML patients having received different consolidation strategies based on either autologous HSCT or chemotherapy only [19]. This evidence concerns the gene NPM1 and acute myeloid leukemia.